p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 701–800 of 1,031
Explaining oscillations and variability in the p53-Mdm2 system
Proctor, C. J., & Gray, D. A. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-75 · Cited by 130
Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification
Park, J., Yang, S. W., Park, J. M., Ka, S. H., Kim, J.-H., Kong, Y., Jeon, Y. J., Seol, J. H., & Chung, C. H. (2016) · Nature Communications · doi:10.1038/ncomms12513 · Cited by 118
Apoptosis — Molecular mechanisms and biomedical implications
McConkey, D. J., Zhivotovsky, B., & Orrenius, S. (1996) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(95)00006-2 · Cited by 119
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
Dowell, S. P., Wilson, P., Derias, N. W., Lane, D. P., & Hall, P. A. (1994) · PubMed · Cited by 119
Self-citationMechanisms of biliary carcinogenesis: A pathogenetic multi-stage cascade towards cholangiocarcinoma
Holzinger, F., Z’graggen, K., & Büchler, M. W. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s122 · Cited by 110
Hughes, P. E., Alexi, T., Yoshida, T., Schreiber, S. S., & Knüsel, B. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00174-1 · Cited by 110
Apoptosis and cancer chemotherapy
Hickman, J. A., Potten, C. S., Merritt, A. J., & Fisher, T. C. (1994) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1994.0112 · Cited by 109
Wheeler, J. A., Stephens, L. C., Tornos, C. S., Eifel, P. J., Ang, K. K., Milas, L., Allen, P. K., & Meyn, R. E. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)00156-s · Cited by 115
Hanot, M., Tubeuf, E., Guilbert, A., Bado‐Nilles, A., Vigneron, P., Trouiller, B., Braun, A., & Lacroix, G. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.01.013 · Cited by 110
“It plays a central role in DNA repair and cell cycle arrest, thereby preventing mutagenic events favoring the process of carcinogenesis (Lane, 1992).”
BackgroundTherapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
Kim, R., Emi, M., Tanabe, K., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20696 · Cited by 114
Hashimoto, T., Tokuchi, Y., Hayashi, M., Kobayashi, Y., 西田, 一., Hayashi, S., Ishikawa, Y., Tsuchiya, S., Nakagawa, K., Hayashi, J., et al. (1999) · PubMed · Cited by 109
p53-mediated protective responses to UV irradiation
Smith, M. L., & Fornace, A. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12255 · Cited by 110
Integrating the DNA damage and protein stress responses during cancer development and treatment
Gorgoulis, V. G., Pefani, D., Pateras, I. S., & Trougakos, I. P. (2018) · The Journal of Pathology · doi:10.1002/path.5097 · Cited by 108
Guo, X., Li, Y., Yan, J., Ingle, T. M., Jones, M. Y., Mei, N., Boudreau, M. D., Cunningham, C. K., Abbas, M., Paredes, A. M., et al. (2016) · Nanotoxicology · doi:10.1080/17435390.2016.1214764 · Cited by 108
“It has been shown that, direct DNA damage can activate the p53 gene to initiate apoptosis (Li et al., 2008) and cells deficient in the p53 gene may escape the apoptotic process, leading to more resistance to cytotoxic damage (Honma et al., 1997; Lane, 1992).”
BackgroundNucleic acid drug vectors for diagnosis and treatment of brain diseases
Lu, Z.-G., Shen, J., Yang, J., Wang, J.-W., Zhao, R.-C., Zhang, T.-L., Guo, J., & Zhang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01298-z · Cited by 106
Rebel, H. G., Mosnier, L. O., Berg, R. J. W., Vries, A. W.-D., STEEG, H. V., van Kranen, H. J., & de Gruijl, F. R. (2001) · PubMed · Cited by 123
Regulation of the p53-MDM2 pathway by 14-3-3 σ and other proteins
Lee, M., & Lozano, G. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.03.009 · Cited by 125
p21 delays tumor onset by preservation of chromosomal stability
Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606343104 · Cited by 110
Hu, T., Miller, C. M., Ridder, G. M., & Aardema, M. J. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(99)00077-9 · Cited by 108
Hupp, T. R., & Lane, D. P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.30.18165 · Cited by 108
Self-citationBannister, A. J., Gottlieb, T. M., Kouzarides, T., & Jackson, S. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.5.1289 · Cited by 107
Sorrell, A. D., Espenschied, C. R., Culver, J. O., & Weitzel, J. N. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0020-0 · Cited by 107
Uversky, V. N. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00006 · Cited by 112
“Although p53 is best known for its role as a tumor suppressor and guardian of the genome (Lane, 1992), besides induction of cell-cycle arrest, apoptosis, or DNA repair, it is also involved in many other cellular processes, including senescence and differentiation (Vousden and Prives, 2009). p53…”
BackgroundMoving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 115
Evidence That Dynamin-2 Functions as a Signal-Transducing Gtpase
Fish, K. N., Schmid, S. L., & Damke, H. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.1.145 · Cited by 107
“Greater than 50% of human cancers carry mutations in p53 and given its central role in responding to cellular insults, it has been referred to as the cellular gatekeeper (Levine, 1997) or guardian of the genome (Lane, 1992).”
BackgroundOffer, H., Erez, N., Zurer, I., Tang, X., Milyavsky, M., Goldfinger, N., & Rotter, V. (2002) · Carcinogenesis · doi:10.1093/carcin/23.6.1025 · Cited by 106
Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-up
Barbareschi, M., Caffo, O., Veronese, S. M., Leek, R., Fina, P., Fox, S. B., Bonzanini, M., Girlando, S., Morelli, L., Eccher, C., et al. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90307-x · Cited by 107
Perwez Hussain, S., & Harris, C. C. (2006) · Journal of Nippon Medical School · doi:10.1272/jnms.73.54 · Cited by 107
Induction of c-fos Proto-oncogene in Mesangial Cells by Cadmium
Wang, Z., & Templeton, D. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.73 · Cited by 115
DeNardo, S. J., Kukis, D. L., Kroger, L. A., O’Donnell, R. T., Lamborn, K. R., Miers, L. A., DeNardo, D. G., Meares, C. F., & DeNardo, G. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4000 · Cited by 109
Sturm, I., Petrowsky, H., Volz, R., Lorenz, M., Radetzki, S., Hillebrand, T., Wolff, G., Hauptmann, S., Dörken, B., & Daniel, P. T. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2272 · Cited by 118
Molecular crosstalk between cancer and neurodegenerative diseases
Seo, J., & Park, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03428-3 · Cited by 113
Murahashi, S., Akiyoshi, T., Sano, T., Fukunaga, Y., Noda, T., Ueno, M., & Zembutsu, H. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0941-4 · Cited by 113
USP7 - a crucial regulator of cancer hallmarks
Saha, G., Roy, S., Basu, M., & Ghosh, M. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188903 · Cited by 101
Sun, X., Shimizu, H., & Yamamoto, K.-I. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4489 · Cited by 122
Yount, G. L., Haas-Kogan, D. A., Vidair, C. A., Haas, M., Dewey, W. C., & Israel, M. A. (1996) · PubMed · Cited by 117
Cell cycle regulation in response to DNA damage in mammalian cells: A historical perspective
Murnane, J. P. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690208 · Cited by 115
Milne, D. M., Palmer, R. H., & Meek, D. W. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.21.5565 · Cited by 107
Gannon, H. S., Woda, B. A., & Jones, S. N. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.011 · Cited by 105
“The p53 tumor suppressor has been called the ‘‘guardian of the genome’’ due to its ability to prevent genotoxic insults from inducing heritable alterations in damaged cells (Lane, 1992).”
Therapeutic targeting of cancer cell cycle using proteasome inhibitors
Rastogi, N., & Mishra, D. P. (2012) · Cell Division · doi:10.1186/1747-1028-7-26 · Cited by 121
The interaction of p53 with replication protein A mediates suppression of homologous recombination
Romanova, L. Y., Willers, H., Blagosklonny, M. V., & Powell, S. N. (2004) · Oncogene · doi:10.1038/sj.onc.1207982 · Cited by 95
“The p53 tumor suppressor, also named a ‘guardian of the genome’ (Lane, 1992), plays a pivotal role in the maintenance of genomic stability and suppression of cellular transformation.”
BackgroundNuclear accumulation and activation of p53 in embryonic stem cells after DNA damage
Solozobova, V., Rolletschek, A., & Blattner, C. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-46 · Cited by 104
Ancient Genomes, Wise Bodies, Unhealthy People: Limits of a Genetic Paradigm in Biology and Medicine
Strohman, R. C. (1993) · Perspectives in biology and medicine · doi:10.1353/pbm.1994.0003 · Cited by 119
Early detection of lung cancer: role of biomarkers
Brambilla, C., Fievet, F., Jeanmart, M., de Fraipont, F., Lantuéjoul, S., Frappat, V., Ferretti, G., Brichon, P. Y., & Moro‐Sibilot, D. (2003) · European Respiratory Journal · doi:10.1183/09031936.02.00062002 · Cited by 126
“P53 has been called "guardian of the genome" [49, 50], as once it is activated, as a result of genotoxic stress, it reduces Rb phosphorylation and induces a stop at the G1-S check-point to allow DNA repair or to drive the cell to an apoptotic programme through bax/bcl2 and other P53-induced gene regulation processes.”
BackgroundAloni-Grinstein, R., Schwartz, D., & Rotter, V. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07125.x · Cited by 114
Liu, G., & Chen, X. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1398-1413.2006 · Cited by 104
Ramadoss, S., Guo, G., & Wang, C.-Y. (2016) · Oncogene · doi:10.1038/onc.2016.174 · Cited by 115
Uddin, M. B., Roy, K. R., Hosain, S. B., Khiste, S., Hill, R. A., Jois, S. D. S., Zhao, Y., Tackett, A. J., & Liu, Y. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.12.014 · Cited by 105
Gounder, M. M., Bauer, T. M., Schwartz, G. K., Weise, A. M., LoRusso, P., Kumar, P., Tao, B., Hong, Y., Patel, P., Lu, Y., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01285 · Cited by 99
Alterations of theTP53Gene in Gastric and Esophageal Carcinogenesis
Bellini, M. F., Cadamuro, A. C. T., Succi, M., Proença, M. A., & Silva, A. E. (2012) · BioMed Research International · doi:10.1155/2012/891961 · Cited by 108
“When activated, in response to cellular stress (Figure 1), p53 triggers adequate cellular response, including cell-cycle arrest, DNA repair and programmed cell death (apoptosis) [19], and preventing the multiplication of damaged cells [20], being named “the guardian of the genome” [21].”
BackgroundConstantinou, A. I., Kamath, N., & Murley, J. S. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00198-1 · Cited by 116
Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.
Lin, D., Fiscella, M., O'Connor, P. M., Jackman, J., Chen, M., Luo, L. L., Sala, A., Travali, S., Appella, E., & Mercer, W. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.10079 · Cited by 104
Uberti, D., Belloni, M., Grilli, M., Spano, P., & Memo, M. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00042.x · Cited by 106
“Upon certain conditions, including physical or chemical DNA damage, p53 gene expression can be activated to either arrest cell cycle progression in the late G1 phase, thus allowing the DNA to be repaired before its replication, or induce apoptosis (Lane, 1992).”
BackgroundWillers, H., McCarthy, E. E., Wu, B., Wunsch, H., Tang, W., Taghian, D. G., Xia, F., & Powell, S. N. (2000) · Oncogene · doi:10.1038/sj.onc.1203142 · Cited by 113
“In many cell types, the dominant cellular response pathway is the G1 cell cycle arrest which is mediated by up-regulation of p21 (Kastan et al., 1992; El-Deiry et al., 1993) and which is assumed to allow for adequate repair of damaged DNA before entering S phase (Lane, 1992; Sherr, 1996).”
BackgroundCasenghi, M., Mangiacasale, R., Tuynder, M., Caillet-Fauquet, P., Elhajouji, A., Lavia, P., Mousset, S., Kirsch‐Volders, M., & Cundari, E. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4554 · Cited by 117
p53 Modulates the Exonuclease Activity of Werner Syndrome Protein
Brosh, R. M., Karmakar, P., Sommers, J. A., Yang, Q., Wang, X. W., Spillare, E. A., Harris, C. C., & Bohr, V. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103332200 · Cited by 105
McCarthy, S. A., Symonds, H., & Dyke, T. V. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3979 · Cited by 116
Dumaz, N., Stary, A., Soussi, T., Daya–Grosjean, L., & Sarasin, A. R. (1994) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(94)90311-5 · Cited by 112
Protein phosphorylation in apoptosis
Gjertsen, B. T., & Døskeland, S. O. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(95)00117-b · Cited by 112
SUMOylation of hnRNP‐K is required for p53‐mediated cell‐cycle arrest in response to DNA damage
Lee, S. W., Lee, M. H., Park, J. H., Kang, S. H., Yoo, H. M., Ka, S. H., Oh, Y. M., Jeon, Y. J., & Chung, C. H. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.293 · Cited by 121
“The p53 tumour suppressor plays a pivotal role in maintenance of genome integrity under cellular stresses, such as DNA damage (Lane, 1992; Lakin and Jackson, 1999; Kruse and Gu, 2009; Levine and Oren, 2009).”
Reed, N., Balega, J., Barwick, T. D., Buckley, L., Burton, K., Eminowicz, G., Forrest, J., Ganesan, R., Harrand, R. L., Holland, C. M., et al. (2020) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2020.08.020 · Cited by 121
Ma, O., Cai, W.-W., Zender, L., Dayaram, T., Shen, J., Herron, A. J., Lowe, S. W., Man, T.-K., Lau, C. C., & Donehower, L. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2929 · Cited by 103
p53 responsive elements in human retrotransposons
Harris, C. R., DeWan, A., Zupnick, A., Normart, R., Gabriel, A., Prives, C., Levine, A. J., & Hoh, J. (2009) · Oncogene · doi:10.1038/onc.2009.246 · Cited by 102
“For this reason, p53 has been known as the guardian of the genome (Lane, 1992).”
BackgroundDNA damage and repair: consequences on dose-responses
Moustacchi, E. (2000) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s1383-5718(99)00164-3 · Cited by 128
Slebos, R. J. C., Hoppin, J. A., Tolbert, P. E., Holly, E. A., Brock, J. W., Zhang, R. H., Bracci, P. M., Foley, J. F., Stockton, P., McGregor, L. M., et al. (2000) · PubMed · Cited by 114
The paradigm of mutant p53-expressing cancer stem cells and drug resistance
Shetzer, Y., Solomon, H., Koifman, G., Molchadsky, A., Horesh, S., & Rotter, V. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu073 · Cited by 110
Yu, G., Luo, H., Zhang, N., Wang, Y., Li, Y., Huang, H., Liu, Y., Hu, Y., Liu, H., Zhang, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246268 · Cited by 110
Colorectal Cancer and the Relationship Between Genes and the Environment
Heavey, P., McKenna, D. J., & Rowland, I. R. (2004) · Nutrition and Cancer · doi:10.1207/s15327914nc4802_2 · Cited by 115
Neužil, J., Dong, L., Ramanathapuram, L. V., Hahn, T., Chladova, M., Wang, X., Zobalová, R., Procházka, L., Gold, M., Freeman, R., et al. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.02.003 · Cited by 111
Regulation of p53 tetramerization and nuclear export by ARC
Foo, R. S.-Y., Nam, Y.-J., Ostreicher, M. J., Metzl, M. D., Whelan, R. S., Peng, C.-F., Ashton, A. W., Fu, W., Mani, K., Chin, S.-F., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710017104 · Cited by 102
de Vicente, J. C., Gutiérrez, L. M. J., Zapatero, A. H., Forcelledo, M. F. F., Hernández, G., & Arranz, J. S. L. (2003) · Head & Neck · doi:10.1002/hed.10339 · Cited by 102
“1) and responsible for the synthesis of a 53-kDa phosphoprotein composed of 393 amino acids, is the best investigated tumor supressor gene.(3) Wild-type p53 protein acts as a DNA-binding transcription factor and leads to the control of the cell cycle by G1/S phase arrest after sublethal DNA damage, thus allowing extra…”
BackgroundWalsh, S. V., Loda, M. F., Torres, C. M., Antonioli, D. A., & Odze, R. D. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199908000-00015 · Cited by 102
Iwashina, M., Shichiri, M., Marumo, F., & Hirata, Y. (1998) · Circulation · doi:10.1161/01.cir.98.12.1212 · Cited by 102
Solar-simulated skin adaptation and its effect on subsequent UV-induced epidermal DNA damage
de Winter, S., Pavel, S., Vink, A. A., & Roza, L. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01478.x · Cited by 101
Iwatate, Y., Hoshino, I., Yokota, H., Ishige, F., Itami, M., Mori, Y., Chiba, S., Arimitsu, H., Yanagibashi, H., Nagase, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0997-1 · Cited by 101
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy
Nakamura, M., Obata, T., Daikoku, T., & Fujiwara, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215482 · Cited by 110
“It had been thought that p53 was an oncoprotein; however, p53 was recognized as a tumor suppressor protein in 1992 [2].”
BackgroundYounes, M., Brown, R. W., Stephenson, M., Gondo, M., & Cagle, P. T. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970915)80:6<1046::aid-cncr6>3.0.co;2-7 · Cited by 381
Wang, J., Zheng, B., Li, X., Ångström, T., Lindström, M. S., & Wallin, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0242 · Cited by 115
Morshed, S. A., Ando, T., Latif, R., & Davies, T. F. (2010) · Endocrinology · doi:10.1210/en.2010-0424 · Cited by 101
Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts
Muganda, P. M., Mendoza, O., Hernandez, J., & Qian, Q. (1994) · Journal of Virology · doi:10.1128/jvi.68.12.8028-8034.1994 · Cited by 101
Maxwell, S. A., & Rivera, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210012200 · Cited by 102
Regulation of transcription factors by protein degradation
Desterro, J. M. P., Rodríguez, M. S., & Hay, R. T. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000760 · Cited by 128
Chompret, A. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01361-x · Cited by 110
p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong, R., Grieu, F., Robbins, P., Dix, B. R., Chen, D., Parsons, R. E., House, A. K., & Iacopetta, B. M. (1997) · PubMed · Cited by 101
Estrada‐Ortiz, N., Neochoritis, C. G., & Dömling, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201500487 · Cited by 97
Regulation of p53 Sequence-specific DNA-binding by Covalent Poly(ADP-ribosyl)ation
Mendoza‐Alvarez, H., & Álvarez-González, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105215200 · Cited by 100
FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage
Chung, Y. M., Park, S.-H., Tsai, W.-B., Wang, S.-Y., Ikeda, M.-A., Berek, J. S., Chen, D. J., & Hu, M. C.-T. (2012) · Nature Communications · doi:10.1038/ncomms2008 · Cited by 98
Furlong, E. E. M., Rein, T., & Martin, F. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5933 · Cited by 110
Longley, D. B., Boyer, J. D., Allen, W. L., Latif, T., Ferguson, P., Maxwell, P. J., McDermott, U., Lynch, M., Harkin, D. P., & Johnston, P. G. (2002) · PubMed · Cited by 120
Kaneko, H., Misawa, S., Horiike, S., Nakai, H., & Kashima, K. (1995) · Blood · doi:10.1182/blood.v85.8.2189.bloodjournal8582189 · Cited by 101
Aberrant phase separation and cancer
Taniue, K., & Akimitsu, N. (2021) · FEBS Journal · doi:10.1111/febs.15765 · Cited by 106
Berke, T. P., Slight, S. H., & Hyder, S. M. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s342292 · Cited by 101
Saed, G. M., Ladin, D., Olson, J., Han, X., Hou, Z., & Fivenson, D. (1998) · Archives of Dermatology · doi:10.1001/archderm.134.8.963 · Cited by 99
“The wild-type gene product also has the ability to arrest growth and/or apoptosis in response to DNA injury, preventing the replication of genomes that have suffered DNA damage.(4-9) Interest in p53 arises from the realization that a wide variety of sporadic human tumors associated with different genetic alterations a…”
BackgroundRegulation of the p53 transcriptional activity
Liu, G., & Chen, X. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20700 · Cited by 100
“Key words: p53; transcription; basal transcriptional machinery; co-activator; co-repressor; post-translational modification p53 is one of the most important tumor suppressors in the cell and often referred to as ‘‘the guardian of the genome’’ [Kastan et al., 1991; Lane, 1992].”
BackgroundOry, B., Blanchard, F., Battaglia, S., Gouin, F., Rédiní, F., & Heymann, D. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028837 · Cited by 103
“Pivotal to the tumor-suppressor activity of p53 is its ability to activate apoptosis via multiple caspase-dependent or caspase-independent pathways (Lane, 1992).”
BackgroundBcl-2 Facilitates Recovery from DNA Damage after Oxidative Stress
Deng, G., Su, J. H., Ivins, K. J., Houten, B. V., & Cotman, C. W. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7145 · Cited by 106
Robles, M. T. S., Symonds, H., Chen, J., & Dyke, T. V. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.4.2686 · Cited by 110
Bauer, J. J., Sesterhenn, I. A., Mostofi, K., McLeod, D. G. R., Srivastava, S. K., & Moul, J. W. (1995) · PubMed · Cited by 99
Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells
Li, Y., Kanki, H., Hachiya, T., Ohyama, T., Irie, S., Tang, G.-L., Mukai, J., & Sato, T.-A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<473::aid-ijc3>3.0.co;2-1 · Cited by 52
Lambkin, H. A., Mothersill, C., & Kelehan, P. (1994) · The Journal of Pathology · doi:10.1002/path.1711720105 · Cited by 105
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.